Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: Multicenter phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in advanced solid tumors

Fig. 3

Kaplan-Meier estimation of survival outcomes as per RECIST version 1.1. Progression-free survival (PFS) and overall survival (OS) across three dose level cohorts (a, b), and PFS and OS stratified by PD-L1 status (c, d). The dosing regimens include 15 mg O + T (onatasertib 15 mg QD + toripalimab 240 mg Q3W), 20 mg O + T (onatasertib 20 mg QD + toripalimab 240 mg Q3W), 30 mg O + T (onatasertib 30 mg QD + toripalimab 240 mg Q3W)

Back to article page